Jinglin Xia

Minhang Branch, 170 Xinsong Road
Minhang, 201199, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 78 publications

LARS promotes hepatocellular carcinoma progression via the PI3K/AKT/mTOR pathway and interaction with RPS5, and serves as a prognostic biomarker.

LARS promotes hepatocellular carcinoma progression via the PI3K/AKT/mTOR pathway and interaction with RPS5, and serves as a prognostic biomarker.

Journal: Molecular medicine (Cambridge, Mass.)

Published: February 10, 2026

β,β-Dimethylacrylshikonin suppresses hepatocellular carcinoma progression through mitochondrial stress and TGM2-associated mitophagy impairment.

β,β-Dimethylacrylshikonin suppresses hepatocellular carcinoma progression through mitochondrial stress and TGM2-associated mitophagy impairment.

Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology

Published: December 14, 2025

GPX8+ cancer-associated fibroblast-derived lactate contributes to lenvatinib resistance by facilitating BRPF1 expression through histone H3 lysine 18 lactylation in hepatocellular carcinoma.

GPX8+ cancer-associated fibroblast-derived lactate contributes to lenvatinib resistance by facilitating BRPF1 expression through histone H3 lysine 18 lactylation in hepatocellular carcinoma.

Journal: Oncogene

Published: August 01, 2025

Targeting JMJD6/PPARγ/GPX4 axis overcomes ferroptosis resistance and enhances therapeutic efficacy in hepatocellular carcinoma.

Targeting JMJD6/PPARγ/GPX4 axis overcomes ferroptosis resistance and enhances therapeutic efficacy in hepatocellular carcinoma.

Journal: Oncogene

Published: May 03, 2025

PIP5K1A Suppresses Ferroptosis and Induces Sorafenib Resistance by Stabilizing NRF2 in Hepatocellular Carcinoma.

PIP5K1A Suppresses Ferroptosis and Induces Sorafenib Resistance by Stabilizing NRF2 in Hepatocellular Carcinoma.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: March 10, 2025

MRI Radiomics to Predict Early Treatment Response to TACE Combined with Lenvatinib Plus a PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.

MRI Radiomics to Predict Early Treatment Response to TACE Combined with Lenvatinib Plus a PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.

Journal: Journal of hepatocellular carcinoma

Published: January 14, 2025

YAP-activated NAT10 promotes hepatoblastoma progression by activating the pentose phosphate pathway.

YAP-activated NAT10 promotes hepatoblastoma progression by activating the pentose phosphate pathway.

Journal: International journal of biological sciences

Published: December 28, 2024

Survival in patients with unresectable hepatocellular carcinoma: TCC cocktail plus TACE vs TACE alone prospective randomized clinical trial.

Survival in patients with unresectable hepatocellular carcinoma: TCC cocktail plus TACE vs TACE alone prospective randomized clinical trial.

Journal: Journal of translational medicine

Published: December 05, 2024

Disulfiram-induced c-FOS influences lipid metabolism and angiogenesis in hepatocellular carcinoma.

Disulfiram-induced c-FOS influences lipid metabolism and angiogenesis in hepatocellular carcinoma.

Journal: Science China. Life sciences

Published: October 12, 2024

Phosphocreatine alleviates monocrotaline-induced liver injury dependent on PSRC1-regulated endoplasmic reticulum stress.

Phosphocreatine alleviates monocrotaline-induced liver injury dependent on PSRC1-regulated endoplasmic reticulum stress.

Journal: Biochemical pharmacology

Published: September 23, 2024

Disulfiram/Cu targeting FOXO6 modulates sensitivity of hepatocellular carcinoma to lenvatinib via disrupt choline metabolic.

Disulfiram/Cu targeting FOXO6 modulates sensitivity of hepatocellular carcinoma to lenvatinib via disrupt choline metabolic.

Journal: Cellular signalling

Published: September 18, 2024

Stimuli-responsive hydrogel microspheres encapsulated with tumor-cell-derived microparticles for malignant ascites treatment.

Stimuli-responsive hydrogel microspheres encapsulated with tumor-cell-derived microparticles for malignant ascites treatment.

Journal: Acta biomaterialia

Published: August 25, 2024

Showing 1-12 of 78

Last Updated: 09/26/2026